Developer of small-molecule innate immune modulators for cancer therapy. It discovers and develops orally available drug candidates that target enzymes and pathways in the innate immune system to treat solid tumors and autoimmune diseases. Its pipeline includes AVA-NP-695 which is ENPP inhibitors and AVA-ADR-001 ADAR inhibitors designed to provide antitumor activity and synergy with checkpoint inhibitors and radiation.
← All startups
Avammune Therapeutics
Series ADeveloper of small-molecule innate immune modulators for cancer therapy. It discovers and develops orally available drug candidates that target enzymes and pathways in the innate immune system to treat solid tumors and autoimmune diseases. Its pipeline includes AVA-NP-695 which is ENPP inhibitors and AVA-ADR-001 ADAR inhibitors designed to provide antitumor activity and synergy with checkpoint inhibitors and…
About
Institutional investors
JITO Incubation & Innovation FoundationTCACapital 2BShastraIvyCap Ventures1CrowdKotak Alternate Asset Managers
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.
Similar startups
Raising like Avammune Therapeutics?
Analyze your pitch deck before your next raise.
Analyze My Deck →